Table 2.
Subgroup analysis of endometrial cancer radiomics studies assessed by RQS and METRICS
| Subgroup analysis | Number of studies | % | Median RQS, (%) | IQR, (%) | p value | Median METRICS, (%) | IQR, (%) | p value | |
|---|---|---|---|---|---|---|---|---|---|
| Modality | 0.13 | 0.13 | |||||||
| MRI | 56 | 82.3 | 33.3 | 25.0–38.9 | 67.6 | 60.9–77.4 | |||
| CT | 5 | 7.4 | 25.0 | 13.9–33.3 | 70.5 | 36.1–79.6 | |||
| PET/CT | 5 | 7.4 | 8.0 | 1.4–30.6 | 53.8 | 30.9–65.4 | |||
| US | 2 | 2.9 | 33.3 | 33.3–33.3 | 78.4 | 69.6–NA | |||
| Year of publication | 0.14 | 0.17 | |||||||
| 2023 | 21 | 30.9 | 33.3 | 25.0–41.7 | 69.9 | 67.3–77.8 | |||
| 2022 | 18 | 26.5 | 33.3 | 19.3–39.6 | 66.8 | 59.4–83.6 | |||
| 2021 | 19 | 27.9 | 30.6 | 19.4–36.1 | 63.4 | 56.1–72.2 | |||
| 2018–2020 | 10 | 14.7 | 25.0 | 10.3–31.3 | 63.3 | 48.9–68.9 | |||
| Topic | 0.59 | 0.32 | |||||||
| Characterisation | 24 | 35.3 | 30.6 | 25.0–41.0 | 69.9 | 63.0–74.7 | |||
| Classification | 10 | 14.7 | 29.2 | 16.3–44.4 | 69.5 | 48.8–78.3 | |||
| Risk stratification | 13 | 19.1 | 33.3 | 27.8–38.9 | 67.5 | 63.0–84.3 | |||
| Prognosis and survival | 8 | 11.8 | 29.2 | 11.8–39.6 | 60.8 | 54.4–68.2 | |||
| Lymph-node involvement | 9 | 13.2 | 31.9 | 10.9–38.2 | 60.8 | 40.6–67.5 | |||
| Others | 4 | 5.9 | 25.0 | 6.9–30.6 | 67.6 | 37.3–83.2 | |||
| Journal quartile | 0.19 | 0.09 | |||||||
| First | 31 | 45.6 | 28.0 | 25.0–36.1 | 71.1 | 60.5–82.8 | |||
| Others | 37 | 54.6 | 33.3 | 19.4–40.3 | 67.5 | 54.9–72.3 |
The studies are divided by imaging modality, year of publication, research topic and journal quartile